Psyence Biomedical Alerted by Nasdaq on Minimum Bid Price Deficiency

Psyence Biomedical Receives Nasdaq Notification

Psyence Biomedical (PBM) has recently received a notification from Nasdaq concerning a minimum bid price deficiency.

Impact of Nasdaq's Notification

The notification emphasizes the urgency for PBM to address the deficiency within a 180-day compliance period.

• Compliance Urgency: Immediate attention required for regulatory compliance to prevent delisting.
• Stock Stability: PBM's stock stability is at risk due to the deficiency, impacting investor confidence.

In conclusion, Psyence Biomedical faces a critical period where swift remedial action is imperative to mitigate the repercussions of the Nasdaq notification.